Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.
Read the guideAn independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.
View the provider overviewOverview & reviewsPrimers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.
View all Learn articlesWhat compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.
A protocol is a goal — recovery, longevity — and the regimen people build toward it: which peptides, why they're combined, how they're dosed and cycled, what to monitor, and, just as important, where the human evidence still runs thin. Written with citations to primary sources, not marketing copy.
The most common soft-tissue "healing stack" pairs BPC-157 with TB-500. Here is what each peptide does, how people actually structure the regimen, what the human evidence does and does not show, how it stacks up against better-studied options — and the regulatory reality, because both are under active FDA review right now.
Read the protocol · 10 min ›Most "longevity" peptide regimens are really one idea: restore the growth-hormone pulse that fades with age, using a GHRH analog paired with a GHRP. Here is how that works, which GHRH partner to weigh (including the one FDA-approved option), what the adult evidence actually supports, the labs that matter, and why the pieces sit in different regulatory buckets.
Read the protocol · 10 min ›